IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LOMBARDI, ROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.947
NA - Nord America 4.864
EU - Europa 3.953
SA - Sud America 546
AF - Africa 120
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 5
Totale 14.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.668
CN - Cina 1.516
SG - Singapore 1.497
GB - Regno Unito 991
IT - Italia 933
HK - Hong Kong 466
BR - Brasile 441
DE - Germania 423
SE - Svezia 414
VN - Vietnam 412
RU - Federazione Russa 355
BD - Bangladesh 334
IN - India 204
FR - Francia 196
NL - Olanda 142
CA - Canada 115
IE - Irlanda 100
FI - Finlandia 96
ID - Indonesia 92
KR - Corea 74
JP - Giappone 71
DK - Danimarca 65
TR - Turchia 61
ES - Italia 42
AR - Argentina 36
IQ - Iraq 33
MX - Messico 33
UA - Ucraina 33
PH - Filippine 31
CI - Costa d'Avorio 30
AT - Austria 26
EG - Egitto 23
AU - Australia 22
BE - Belgio 21
TW - Taiwan 21
PL - Polonia 19
TH - Thailandia 19
PK - Pakistan 17
CH - Svizzera 16
CO - Colombia 14
CL - Cile 13
ZA - Sudafrica 13
VE - Venezuela 12
EC - Ecuador 11
MY - Malesia 11
UZ - Uzbekistan 11
KE - Kenya 10
SA - Arabia Saudita 10
CZ - Repubblica Ceca 9
GR - Grecia 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
DZ - Algeria 8
EU - Europa 8
IR - Iran 8
JO - Giordania 8
LT - Lituania 8
PT - Portogallo 8
PY - Paraguay 8
RO - Romania 8
JM - Giamaica 7
LU - Lussemburgo 7
TN - Tunisia 7
AZ - Azerbaigian 6
SC - Seychelles 6
BG - Bulgaria 5
BO - Bolivia 5
HN - Honduras 5
PR - Porto Rico 5
SN - Senegal 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
EE - Estonia 4
KZ - Kazakistan 4
LK - Sri Lanka 4
MA - Marocco 4
NI - Nicaragua 4
OM - Oman 4
PA - Panama 4
RS - Serbia 4
CY - Cipro 3
ET - Etiopia 3
KG - Kirghizistan 3
MD - Moldavia 3
NO - Norvegia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PE - Perù 3
UY - Uruguay 3
AO - Angola 2
GT - Guatemala 2
IL - Israele 2
LV - Lettonia 2
MM - Myanmar 2
MO - Macao, regione amministrativa speciale della Cina 2
MQ - Martinica 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 14.437
Salva come PNG Salva come JPEG
Città #
Southend 855
Singapore 843
Ashburn 686
Hong Kong 387
Dallas 373
San Jose 344
Chandler 311
Milan 297
Beijing 227
Hefei 183
Council Bluffs 167
Los Angeles 147
Ho Chi Minh City 141
Fairfield 140
New York 120
Santa Clara 113
Wilmington 113
Seattle 111
Ann Arbor 108
Frankfurt am Main 102
Princeton 101
Dublin 99
Boardman 92
Guangzhou 89
Hanoi 89
Lauterbourg 87
Buffalo 84
Bengaluru 83
Dearborn 78
Hanover 77
Houston 77
Moscow 77
Jakarta 67
Woodbridge 67
The Dalles 66
Rome 62
Helsinki 54
Cambridge 52
Toronto 52
Munich 49
Shanghai 48
Chicago 45
São Paulo 43
Tokyo 41
Seoul 39
Istanbul 37
Atlanta 36
Grafing 36
Phoenix 36
Nanjing 35
Da Nang 34
Cangzhou 32
Tianjin 32
Abidjan 30
Columbus 29
Des Moines 29
London 28
Nuremberg 25
Lappeenranta 20
Montreal 20
Turin 20
Denver 19
Jinan 19
Berlin 18
Brussels 18
Changsha 18
Fremont 18
Fuzhou 18
Hebei 18
Naples 18
Brooklyn 17
Genoa 17
Mountain View 17
Shenzhen 17
Washington 17
Bangkok 16
Boston 16
Hangzhou 16
Nanchang 16
Dhaka 15
Silver Spring 15
Amsterdam 14
Cairo 14
Zhengzhou 14
Baghdad 13
Haiphong 13
Mumbai 13
Shenyang 13
Florence 12
Kent 12
Manila 12
Redwood City 12
San Diego 12
Warsaw 12
Wuhan 12
Düsseldorf 11
Sydney 11
Tashkent 11
Tucson 11
Bari 10
Totale 8.540
Salva come PNG Salva come JPEG
Nome #
PNPLA3 I148M polymorphism and progressive liver disease 384
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy 365
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 355
Response of an Italian reference institute to research challenges regarding a new pandemic: COVID-19 network 306
Vascular damage in patients with nonalcoholic fatty liver disease : Possible role of iron and ferritin 278
Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD 276
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 258
High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation : preliminary results 250
Acquired hepatocerebral degeneration (AHD) : a peculiar neurological impairment in advanced chronic liver disease 248
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis 245
Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: a possible marker of metabolic syndrome and early vascular damage 240
Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity 239
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes : evidence in NAFLD patients and cell cultures 234
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly 231
Progressively invalidating orthostatic hypotension : a common symptom for a challenging diagnosis 226
Nutrients, genetic factors, and their interaction in non-alcoholic fatty liver disease and cardiovascular disease 224
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown 218
Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD 216
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy : comment 214
Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature 209
Autonomic dysfunction and SIADH as first signs of Guillain-Barre syndrome 206
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity 205
The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID study 201
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease 199
Key predictors of relevant weight loss in patients with metabolic dysfunction-associated steatotic liver disease 192
An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians 190
Echocardiographic epicardial fat thickness : preliminary results of a prospective study in non-alcoholic fatty liver disease 190
Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis 190
Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis 189
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies 186
Gender-differences in disease distribution and outcome in hospitalized elderly : Data from the REPOSI study 185
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease 184
The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis 183
Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease 182
Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy 177
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity 172
Etiology and severity of liver disease in HIV-positive patients with suspected NAFLD : lessons from a cohort with available liver biopsies 172
Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for {COVID}-19: comment 168
Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences 166
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity 160
Portal hypertension-like pattern in coronavirus disease 2019 acute respiratory distress syndrome 159
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease 158
Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI 157
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors 153
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 153
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 152
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value 146
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease 143
NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes 143
Extrapulmonary tuberculosis : an unusual presentation in an immunocompetent patient 142
Brain involvement in non-alcoholic fatty liver disease (NAFLD) : a systematic review 141
What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives 140
Liver test abnormalities in patients with HIV mono-infection : assessment with simple non-invasive fibrosis markers 138
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): An attempted network meta-analysis 135
The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes 132
A sweet fever 130
Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events : a prospective multicentre study 130
Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIII 126
Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals 126
Spring Meeting of the Young Researchers of SID, SIIA, SIMI, SIPREC, SISA 126
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 125
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes 123
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP) 119
MAFLD and NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality? 116
Role of artificial intelligence in staging and assessing of treatment response in MASH patients 113
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis 112
Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism 111
Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades 111
Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies 107
Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis 106
Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI‑COVID‑19 Registry 104
Nutritional and Lifestyle Therapy for NAFLD in People with HIV 103
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients 100
Global Epidemiology of Hepatitis B Virus (HBV) Infection 100
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility 98
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy : a prospective study 98
Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population 95
Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques 95
Reply to Comment : Is there any place for SGLT2-inhibitors in post-liver transplantation patients? 94
MAFLD and CKD: An Updated Narrative Review 93
Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis 92
Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study 91
Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients 90
Author's Reply: “Bacterial infections predispose to the development of portal vein thrombosis in patients with decompensated cirrhosis” 87
Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD : Fact or Fiction? 84
Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection 72
Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights 68
Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease 63
Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD 62
Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension 62
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B 61
Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study 59
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 54
Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study 53
Two‐tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross‐sectional study 41
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study 39
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study 32
Metabolic dysfunction associated steatotic liver disease (MASLD) treatment: Does lifestyle still matter? 31
Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease 25
Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework 9
Totale 15.041
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.967
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202180 0 0 0 0 0 0 0 0 0 0 0 80
2021/2022836 49 41 45 95 83 45 47 62 101 66 62 140
2022/20231.102 126 128 85 121 112 183 37 93 95 25 72 25
2023/2024767 32 51 34 44 202 46 26 37 34 25 79 157
2024/20252.817 92 294 99 232 152 129 180 245 164 308 332 590
2025/20266.837 641 576 794 557 546 345 785 377 686 509 751 270
Totale 15.041